



## PANCREASURE TEST RECEIVES AMA CPT CODE FOR BILLING AND REIMBURSEMENT

**Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced that the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel has assigned a CPT Proprietary Laboratory Analyses (PLA) code for the company's new PancreaSure test.**

The CPT code for PancreaSure is a Proprietary Laboratory Analyses (PLA) code and becomes effective October 1, 2025 and can then be used for the submission of healthcare claims to third-party payers in the US. It enables payers to efficiently identify, and process claims for PancreaSure, reducing administrative complexity in the billing process.

"Establishing a new CPT code represents an important early step in our US market access strategy," said Jeff Borcharding, CEO. "We're very pleased with the progress we're making, but it is important to understand that this initiates the reimbursement pathway rather than completing it."

Code assignment represents one of three required steps toward Medicare payment. The second step is to obtain a payment rate at which the PancreaSure test would be reimbursed by Medicare. Immunovia presented its pricing recommendation at a public meeting at the Centers for Medicare and Medicaid Services on June 27, 2025. This recommendation is currently under review. The third step to achieving Medicare reimbursement is to secure a positive coverage decision based on the clinical evidence supporting the use of PancreaSure.

### **About AMA CPT codes**

The AMA CPT Editorial Panel assigns HCPCS (Healthcare Common Procedure Coding System) to report medical, surgical, and diagnostic services performed by healthcare professionals. The PLA code set, which comprises a subset of CPT codes, includes unique alphanumeric identifiers assigned by the AMA to proprietary clinical laboratory tests. These codes enable laboratories to submit claims to government and private payers, with each PLA code uniquely identifying a company's specific proprietary test. While assignment of a PLA code is a key milestone in pursuing reimbursement, it does not guarantee coverage or establish payment rates. Revenue generation depends on successful pricing determination and coverage decisions, processes with timelines outside Immunovia's direct control.

### **For further information, please contact**

Jeff Borcharding, CEO

[jeff.borcharding@immunovia.com](mailto:jeff.borcharding@immunovia.com)

**Immunovia in brief**

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.

For more information, please visit [www.immunovia.com](http://www.immunovia.com).